SEC Form 4 · accession 0001209191-19-017560
ChemoCentryx, Inc. · CCXI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas J. Schall
Officer — President and CEO · Director
Period of report
Mar 4, 2019
Accepted (ET)
Mar 6, 2019 · 7:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001340652
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Mar 4, 2019 | A | 70,000 | A | — | — | Common Stock | 70,000 | 70,000 | D |
| Stock Option (right to buy)F4,F3 | $11.02 | Mar 4, 2019 | A | 230,000 | A | — | Mar 4, 2029 | Common Stock | 230,000 | 230,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of CCXI common stock.
- F2The restricted stock units awarded on March 4, 2019, vest in three equal installments on January 1, 2020, January 1, 2021, and January 1, 2022, subject to the Reporting Person's continued service to the Company on such date. Shares will be delivered to the Reporting Person within thirty (30) days following vest date.
- F3The option was granted on March 4, 2019, and 25% of the total number of shares of common stock subject to the option vests on January 1, 2020, and 1/48th of the total number of shares of common stock subject to the option vests monthly thereafter, subject to the Reporting Person's continued service to the Company on each such vesting date.
- F4Not applicable.